Tag: Motley Fool

The Eagle Mountain Mining Ltd (ASX: EM2) share price is dipping today after the company posted an investor presentation. At the time of writing, Eagle Mountain shares are down 3.86% to $1.12 per share.

Eagle Mountain is engaged in the exploration and evaluation of copper, gold, silver, and porphyry copper deposits. Its project portfolios include Silver Mountain and Oracle Ridge across Australia and the United States.

Presentation highlights

The Eagle Mountain share price is failing to respond despite the company honing in on two of its most recent updates. It has moved to 100% ownership of its Oracle Ridge mine after strong recent results in the region sent the Eagle Mountain share price rocketing 12%. The company also revealed its plans to increase its mining operation drilling rates three-fold over the coming quarter.

Eagle Mountain is currently working along four kilometres of mapped and sampled mineralisation in its Leatherwood contact, as part of the Oracle Ridge mine. The company was also bullish about its prospects for the next quarter, saying it has “good credentials to potentially be a low emission mining operation”.

It has an existing underground mine with 18 kilometres of development and extensive local infrastructure within a tier-one mining jurisdiction of Arizona in the US. The release noted that Arizona was recently named the second-most lucrative mining region in the world in investment attractiveness.

The company also reported strong drilling results since September 2020. It’s raised $11 million since February 2021 to fund its drilling operations during 2021, with the company expecting to leverage record high copper prices over the coming months. The copper price is now more than double what it was in January 2020.

Eagle Mountain share price snapshot

Including today, the Eagle Mountain share price has now been tumbling for three days. These losses have, however, been partially mitigated by the company’s huge gains recently. It’s still up almost 11% over the past week and around 65% over the past month.

More reading

• Why is the Eagle Mountain (ASX:EM2) share price flying 13% today?
• Why the Eagle Mountain (ASX:EM2) share price is surging 19% higher again today

Motley Fool contributor Lucas Radbourne-Pugh has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post What’s happening with the Eagle Mountain (ASX:EM2) share price today? appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/3xJHNM6

The CSL Limited (ASX: CSL) share price has been wobbling in recent times following the company’s ongoing plasma collection issues. Investors hit the sell button in February and March after digesting CSL’s half-year results announcement and experiencing a broader market slump thereafter.

While the global biotech’s shares have stabilised for now, the company is still facing headwinds.

At the time of writing, CSL shares are swapping hands for $271.38, up 0.16%.

What’s going on with CSL?

CSL has been in the spotlight receiving heavy media attention about its plasma stockpile, and AstraZeneca plc (NASDAQ: AZN) COVID-19 vaccine update.

First and foremost, CSL’s plasma collections have taken a hit over the past 14 months, adversely impacted by the pandemic. Fewer people are donating blood to the company’s collection centres as countries go into lockdown following new COVID-19 waves.

Plasma, derived from blood, is a key ingredient in the production of life-saving therapies. CSL’s most recent update in March advised that December 2020 plasma volumes stood at 80% of December 2019 levels.

The company has been busy targeting marketing initiatives to increase collections, along with opening new centres.

Only time will tell if the biotech leader can build back up its plasma stockpile in the short-term.

Moving on, CSL provided an update last Saturday on its COVID-19 vaccine manufacturing numbers. It said that over 1 million doses are being produced each week and is scheduled for release in mid-May. This is provided that the required quality checks are approved.

CSL noted that there is about a 4-week quality control and approval process in which each batch is stringently tested. This is undertaken by AstraZeneca, the Australian Therapeutic Goods Administration (TGA) and CSL.

To date, over 3.7 million doses of locally made AstraZeneca COVID-19 vaccines have been released. However, current COVID-19 vaccinations administered across the country stands at around 2.3 million. The remaining 1.4 million vials are either sitting in cold storage or facing transportation delays to clinics and pharmacies.

CSL share price summary

Over the course of the past 12 months, CSL shares have taken investors on a rollercoaster ride, down 9%. The company’s shares are currently sitting just below the mid-range of $242.00 to $320.42 achieved over the year’s timeframe.

On valuation grounds, CSL is the third largest company on the ASX with a market capitalisation of roughly $123 billion.

More reading

• Pssst, I’m a value investor who makes money from growth shares: fundie
• ASX 200 Weekly Wrap: Shares have average week but a great month
• Here’s how the CSL (ASX:CSL) share price performed in April
• Top ASX shares to buy in May 2021
• How to find the best ASX shares on the share market

Aaron Teboneras owns shares of CSL Ltd. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Why the CSL (ASX:CSL) share price is seesawing over the past month appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/2RkLgjM

The Transurban Group (ASX: TCL) share price has fallen out of favour in recent months. This has primarily been due to a lack of capital gains and dividends. Consequently, the company has been overshadowed by ASX 200 shares such as BHP Group Ltd (ASX: BHP).

However, the company’s investor presentation this week revealed positive traffic trends and a number of near-term growth initiatives.

Could this put the Transurban share price back in the spotlight as a top dividend stock? 

Investor briefing 

Transurban’s investor presentation notes that emerging indicators in Australian markets suggest that working from home is not going to fundamentally alter long-term traffic growth.

Its findings observe movements in central business districts continuing to recover and peak hour traffic patterns looking similar to pre-COVID. The company also notes that the preference for private vehicle travel over public transport may be enduring. It is believed that this is primarily due to concerns about personal safety. The recent growth in new and used car sales and car ownership supports the view that public transport diversion is likely to continue. 

Transurban highlighted a number of opportunities in the pipeline in Australia and North America. In the next five years, the company is exploring the acquisition of the NSW Government’s 49% stake in WestConnex, M7 staged widening and an M7/M12 interchange. Near-term growth opportunities also exist in North America where a number of express lane extensions and acquisition opportunities are available. 

Broker weighs in on the Transurban share price

Macquarie found the investor briefing to be more strategic rather than financial in nature. The broker observes the significant number of major projects and pipeline. Furthermore, the agenda is likely to expand as governments deal with congestion. 

Macquarie points to growing possibilities. These include the Beach Link in NSW, North Eastern in Victoria, and the 2032 Olympic bid in Brisbane. 

Despite the growth opportunities and outperform rating, the broker’s target price of $14.51 represents an upside of just ~3.5%. Macquarie is forecasting a full year FY21 dividend of 40.20 cents, which represents a yield of 2.87% at today’s prices. 

More reading

• The ASX’s China problem is getting worse… and quickly
• 2 quality ASX dividend shares that will help you beat low interest rates
• ASX 200 up 0.25%: Westpac result impresses, PointsBet jumps
• Deterra (ASX:DRR) share price outperforms on royalty update
• ASX miners set for tough start even as commodity premiums hit a 14-year high

Motley Fool contributor Kerry Sun has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of and has recommended Macquarie Group Limited. The Motley Fool Australia owns shares of Transurban Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Is the Transurban (ASX:TCL) share price a buy for dividends? appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/3uj3HUz

On Monday I looked at three ASX shares that brokers have given buy ratings to this week.

Unfortunately, not all shares are in favour with them right now. Three that have just been given sell ratings are listed below. Here’s why these brokers are bearish on these ASX shares:

Bubs Australia Ltd (ASX: BUB)

According to a note out of Citi, its analysts have retained their sell rating and 35 cents price target on this infant formula company. This follows the release of a mixed third quarter update last week. The broker continues to believe that Bubs is in a difficult spot due to challenging market conditions in China which is seeing domestic players outperforming. Especially given how small its brand is. Furthermore, it feels that China’s declining birth rate means the market could contract in the near future. The Bubs share price is trading at 40 cents today.

Paradigm Biopharmaceuticals Ltd (ASX: PAR)

A note out of Morgans reveals that its analysts have retained their reduce rating and $1.69 price target on this biopharmaceutical company’s shares. According to the note, the broker wasn’t surprised to see the US FDA put Paradigm’s investigational new drug (IND) application on hold. Morgans believes that a decision could be months away, which will lead to further cash burn and uncertainty. The broker has previously stated that it sees risk to the viability of the company’s osteoarthritis drug as a commercial asset. The Paradigm share price is fetching $2.33 today.

Premier Investments Limited (ASX: PMV)

Analysts at Goldman Sachs have retained their sell rating and $20.20 price target on this retail conglomerate’s shares. This follows an update on its JobKeeper payment and guidance for FY 2021. According to the note, Premier Investments’ earnings before interest and tax guidance of $318 million is largely in line with its estimates. However, this doesn’t change its view on the company. With Goldman expecting its earnings to fall materially in FY 2022 and then remain flat into FY 2023, it feels its shares are expensive at the current level. The Premier Investments share price is trading at $26.12 this afternoon.

More reading

• Brokers point to these ASX 200 shares to beat the market in May
• The ASX’s China problem is getting worse… and quickly
• ASX 200 flat, Westpac rises after HY21, Premier returns jobkeeper
• Why Bubs, IDP Education, ResMed, & Tyro shares are dropping today
• Premier Investments (ASX:PMV) share price lower after JobKeeper update

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of BUBS AUST FPO. The Motley Fool Australia owns shares of and has recommended Premier Investments Limited. The Motley Fool Australia has recommended BUBS AUST FPO. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Leading brokers name 3 ASX shares to sell today appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/3ugiRde

The S&P/ASX 200 Index (ASX: XJO) is on form on Tuesday and on course to record a decent gain. In afternoon trade, the benchmark index is up 0.4% to 7,056.3 points.

Four ASX shares that have failed to follow the market higher today are listed below. Here’s why they are sinking:

AnteoTech Ltd (ASX: ADO)

The AnteoTech share price is down 7.5% to 36.5 cents. This is despite there being no news out of the biotechnology company. However, with the company’s shares up a sizeable 40% over the last 30 days (even after today’s decline), profit taking could be weighing on them today.

Domain Holdings Australia Ltd (ASX: DHG)

The Domain share price is down 3.5% to $4.90. This morning analysts at Goldman Sachs retained their hold rating and $4.04 price target on the property listings company’s shares. The broker’s research indicates that Domain is increasing prices by 4% in the Inner Sydney market, but with no other changes/inclusions to agent contracts. This is smaller than the 8% increase by rival REA Group Limited (ASX: REA).

Flight Centre Travel Group Ltd (ASX: FLT)

The Flight Centre share price has fallen 3.5% to $16.32 following the release of a third quarter update. The travel agent revealed that trading was subdued in January and February before rebounding in March. However, this won’t be enough for an improvement in its second half result. Management expects to report an underlying second half loss in line with the one recorded in the first half.

Nick Scali Limited (ASX: NCK)

The Nick Scali share price is down 5% to $10.18. This is despite the furniture retailer releasing a trading update and revealing that its year to date revenue growth was ~44% to 30 April. Positively, more of the same is expected in the fourth quarter, which is expected to result in net profit of $78 million to $80 million in FY 2021. This will be increase of approximately 85% to 90% on the previous financial year. It appears as though some investors were expecting an even stronger performance.

More reading

• ASX 200 up 0.2%: SEEK hits record high, Flight Centre tumbles
• Nine (ASX:NEC) share price edges higher on third quarter update
• Flight Centre (ASX:FLT) share price lower following Q3 update
• Why the Nick Scali (ASX:NCK) share price will be on watch today
• 2 high quality blue chip ASX 200 shares rated as buys

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Flight Centre Travel Group Limited and REA Group Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Why AnteoTech, Domain, Flight Centre, & Nick Scali are sinking today appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/3b0qvke

Some investors might think May is the time to “sell and go away”. However, here are the ASX 200 shares brokers think could beat the market. 

ASX 200 shares to buy in May 

Graincorp Ltd (ASX: GNC)

The typically slow-moving Graincorp share price is up a surprising 20% year-to-date. Its shares lifted into 8-year highs following a positive business update that upgraded 2023-24 earnings by an additional $25 million.

In anticipation of its first-half results on 13 May, Morgans is forecasting earnings before interest, taxes, depreciation, and amortisation (EBITDA)  growth of 29%. This is underpinned by a record east coast grain crop and further contributions from its strategic initiatives. 

Furthermore, the broker retained an add rating with a target price of $6.17. The Graincorp share price is currently fetching for $5.21. 

Northern Star Resources Ltd (ASX: NST)

The Northern Star share price has steadily pushed lower on the back of weaker gold prices. However, the company continues to perform well operationally with a recent 8% increase in reserves to 21Moz.

Macquarie, impressed by the upgrades, believes there is considerable upside to long-term forecasts. An outperform rating was retained with a $12.20 target price.

The Northern Star share price is down 20% year-to-date and are currently trading for $10.93 at the time of writing. 

Premier Investments Limited (ASX:PMV)

Macquarie has upgraded its estimates for retail earnings by 3.2%. The broker believes underlying trading is exceeding expectations and is confident in the company’s ability to meet current consensus forecasts. 

More recently, Premier Investments announced that it will repay $15.6 million in JobKeeper benefits following strong trading performance offsetting the costs of recent lockdowns in Queensland and Western Australia. 

The broker is bullish on Premier Investments shares with an outperform rating and a $31 target price.

Its shares are currently trading at $26.13, not far off its record all-time high of $27.33. 

Seven West Media Ltd (ASX: SWM)

Seven’s third-quarter trading update highlights TV advertising revenue growth at the upper end of the guidance range of 7-10%. Its net debt guidance by the end of FY21 was also better than what Credit Suisse had expected. 

The broker believes Seven is cycling through easy FY20 comparables and forecasts 20% growth in TV advertising in the second half. An outperform rating was retained with a target price of 80 cents. This represents a significant upside compared to its current trading price of 48 cents. 

At the time of writing, Seven’s share price is trading for 47 cents. 

More reading

• Why De Grey, Infomedia, Northern Star, & SEEK shares are storming higher
• Pssst, I’m a value investor who makes money from growth shares: fundie
• 5 things to watch on the ASX 200 on Tuesday
• How the gold price is impacting these ASX gold shares
• ASX 200 flat, Westpac rises after HY21, Premier returns jobkeeper

Motley Fool contributor Kerry Sun has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of and has recommended Macquarie Group Limited and Premier Investments Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Brokers point to these ASX 200 shares to beat the market in May appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/3vE9HHB

The Coles Group Ltd (ASX: COL) share price is having a pretty happy day today. Coles shares are up 1.6% to $16.52 at the time of writing. As all good dividend investors would know, higher share prices equal lower dividend yields. And with today’s move, the trailing dividend yield investors can expect from new Coles shares is now at 3.66%.

But Coles can still be considered a great ASX dividend share. Here are 3 reasons why

3 reasons Coles is a top ASX dividend share

Dividend safety

Coles is a consumer staples company. It mostly sells products that we need, rather than want. That’s food, drinks and household essentials, as well as tobacco and alcohol. These products are highly inelastic, essentially recession-proof, and extremely resilient to any other form of economic malady. That includes inflation too. All of these factors make Coles’ revenue and earnings very stable – which in turn, makes Coles’ dividends stable. We saw this in play last year. While most ASX blue chip shares like the banks were slashing dividends, Coles managed to raise its own. And that leads us to our second point…

Coles’ dividend is growing

In the few years since finding its ASX independence from its old parent Wesfarmers Ltd (ASX: WES), Coles has proven itself to be a strong ASX dividend growth share. Its final dividend from 2019 came in at 24 cents a share. Its interim dividend in 2020 was 30 cents per share. Contrast that with its last final and interim dividends, which were 27.5 cents and 33 cents a share respectively. That’s an average growth rate of 12% per annum. There are not too many ASX dividend shares out there that have even kept their dividend steady over 2019-2021 – including Woolworths Group Ltd (ASX: WOW). Let alone grown them at that pace.

There’s still a decent yield to consider

Coles’ current trailing dividend yield of 3.66% is still pretty high by today’s ASX standards. And when you factor in Coles’ full franking, that yield rises to 5.24% grossed-up. And again, compared to Woolworths, Coles shines. Woolworths shares are only offering a dividend yield of 2.57% on current pricing.

Considering interest rates remain at near-zero levels, and look to continue that way for at least a year or two, a dividend yield that high is certainly useful. Compared to a term deposit that might yield 0.9% if you’re lucky, Coles certainly brings home the bacon in this department.

More reading

• Vicinity (ASX:VCX) sees improvements as it struggles back to COVID-normal
• 2 of the best ASX 200 blue chip shares to buy today
• ASX 200 Weekly Wrap: Shares have average week but a great month
• Top brokers name 3 ASX shares to buy next week
• 2 buy-rated ASX dividend shares to snap up in May

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of COLESGROUP DEF SET, Wesfarmers Limited, and Woolworths Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post 3 reasons why Coles (ASX:COL) is a top ASX dividend share appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/3nREwWD

The Coronado Global Resources Inc (ASX: CRN) share price remains frozen today after the company released its equity offer presentation to investors. The coal producer is seeking $100 million in refinancing funds.

Coronado shares have been paused at $60 cents since the company entered a trading halt on 29 April, after falling more than 33% the past month. 

Coronado produces high-quality metallurgical coal, an essential element in the production of steel. The company owns a portfolio of operating mines and development projects in Queensland and also holds interests in Virginia and West Virginia in the United States.

What Coronado’s refinancing means

Coronado’s coal mining operations have been hit – along with all other coal producers – by the ramp-up in renewable energy focus in 2021 by governments across the world.

The company’s Queensland operations were also impacted by China’s ban on Australian coal exports, although as an international company, it was better suited to weather those hits. 

The company has today included a US$100 million equity transaction as part of its proposed refinancing package, which will exist as a multi-currency asset-based loan.

This is part of a broader proposed US$550 million refinancing package that the company expects, when completed, will create a capital structure that is “flexible through market cycles with… specific benefits to Coronado stakeholders”.

In the company’s words, it hopes to use the cash to create “increased financial flexibility, an extended maturity profile; diversified funding sources; and the maintenance of liquidity for the business and a reduced net debt level”.

Coronado management comments

Coronado CEO Gerry Spindler said the refinancing was good news for the embattled company.

We are very pleased with the support we have received from investors across the globe after what has been a very difficult period for producers in the metallurgical coal sector.

This refinancing package will leave Coronado very well placed to deliver value to stakeholders as the global economy continues to recover following the COVID-19 pandemic and the demand for steel-making coal continues to improve.

Coronado share price snapshot

The Coronado share price is down across every time metric, losing 6% over the past week, 33% the past month, 47% in 2021 so far and over the past 12 months, while it’s also down more than 90% against the basic materials sector.

More reading

• Why the Future First Technologies (ASX:FFT) share price is surging 5%
• Why is the Cyclopharm (ASX:CYC) share price down today?
• MLG Oz (ASX:MLG) shares rocket 36% on ASX IPO
• The MyDeal (ASX:MYD) share price is flying today. Here’s why
• Impedimed (ASX:IPD) share price bounces on ‘significant’ hospital finding

Motley Fool contributor Lucas Radbourne-Pugh has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Coronado (ASX:CRN) share price freeze on $100m refinancing news appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/2SjXmtH

The Future First Technologies Ltd (ASX: FFT) share price is surging today. This comes after the company announced it has been awarded a significant contract for its Software-as-a-Service (SaaS) platform.

At the time of writing, the IT professional services provider’s shares are trading at 8.5 cents, up 19.7%.

What’s driving the Future First Technologies share price?

Investors are snapping up Future First Technologies shares as the company looks set to boost revenue growth.

According to its release, Future First Technologies advised its wholly-owned subsidiary, Asset Vision has signed a multi-year contract with Ventia.

A 50% owned associate of the Cimic Group Ltd (ASX: CIM), Ventia is one of the largest infrastructure service providers in Australia and New Zealand. The company specialises in the long-term operation, maintenance, and management of critical roads and private assets.

Under the agreement, Asset Vision will supply its industry-leading intelligent SaaS platform across a number of Ventia’s roads. The software solution will play a vital role in keeping roads and transport assets safe and reliable for community use. It connects assets owners, maintainers, and contractors together to provide an integrated view of the transport infrastructure. In addition, the platform can also be combined with a dedicated mobile app for workforce management, allowing maintenance crews and inspectors to work safely.

Initially, Asset Vision will provide the SaaS platform across roads in Queensland, where the majority of upgrade works are occurring. The company’s existing footprint expands over Victoria and New South Wales, where it also supplies its SaaS platform.

The deal will run for a period of 3 years, with an attached two-year extension if agreed by both parties. Other potential Ventia road contracts may also be included depending on the success of the contract.

Furthermore, Future First Technologies expects to generate more than $2 million in revenue from the initial part of the deal.

What did management say?

Ventia group executive of transport, Peter Borden touched on the new agreement, saying:

We have worked with Asset Vision since 2020 and have been impressed with the platform and quality of their team. Asset Vision understands our core needs and is aligned in building cost-effective and innovative outcomes for Ventia and our clients.

Future First Technologies CEO, Keith Falconer continued on to add:

To be selected by an industry leader such as Ventia is a satisfying endorsement of the strategic direction of FFT and we look forward to the future with growing confidence in our technology and people.

Future First share price snapshot

Formerly known as PS&C Ltd, the company’s shares have accelerated in the past 12 months, up 180%. When looking at year-to-date performance, the Future First Technologies share price has gained around 60%.

On valuation metrics, Future First Technologies has a market capitalisation of roughly $38 million, with approximately 553.1 million shares outstanding.

More reading

• ASX 200 Weekly Wrap: Shares have average week but a great month
• These were the best performing ASX 200 shares last week
• Why the CIMIC (ASX:CIM) share price has see-sawed this morning
• Here’s why the Cimic (ASX:CIM) share price is pushing higher today

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Why the Future First Technologies (ASX:FFT) share price is surging 5% appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/3vEB4Bw

The Cyclopharm Limited (ASX: CYC) share price is dipping today after the company released its 2021 AGM Presentation.

Cyclopharm shares are down 1% to $2.82 at the time of writing, after gaining more than 10% over the past week.

Cyclopharm Ltd is an Australia-based company that engages in the manufacture and sale of medical equipment and radiopharmaceuticals, including associated research and development.

Highlights from Cyclopharm’s market update

Cyclopharm reported significant metrics in its AGM, noting record group sales revenue in 2020 of $14.7 million, up 4.2% on 2019. It recorded $2.2 million of new third‐party distribution revenue in its Technegas distribution network.

Overall, Technegas sales rebounded by 51.4% in the second half of 2020, after a pandemic-impacted first half. The company reported a $5.8 million net loss before tax. The company’s February 2021 capital raising placement was oversubscribed, raising $33 million in total.

Cyclopharm AGM Chair’s address

Cyclopharm Chair, David Heaney, expanded on the company’s rebound from COVID-19.

2020 was a pivotal year for Cyclopharm. Despite the challenges we faced from a global coronavirus pandemic, we have expanded our global footprint to  include sales into over 60 countries, and proudly, our Technegas products have now been used in over 4.3 million patient procedures globally. We also commenced operations as a distributor of third party products in Europe, leveraging our existing distribution capabilities.

Together with our existing Technegas revenues, this new income stream enabled Cyclopharm to report record revenues in 2020 of $14.7 million. Our strong underlying sales performance supported the Board’s decision to maintain our full year dividend at 1.0 cent per share.

Background on Cyclopharm’s business model

Cyclopharm operates through two segments. Its Technegas segment involves supplying diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism. Meanwhile, its Molecular Imaging segment produces radiopharmaceuticals to be used by physicians in the detection of cancer, neurological disorders, and cardiac disease. The company generates maximum revenue from the Technegas segment.

Cyclopharm share price snapshot

The Cyclopharm share price has had a good run recently, up 10% in the past week, 11% the past month, 14% in 2021 so far and 146% over the past 12 months. 

More reading

• MLG Oz (ASX:MLG) shares rocket 36% on ASX IPO
• The MyDeal (ASX:MYD) share price is flying today. Here’s why
• Impedimed (ASX:IPD) share price bounces on ‘significant’ hospital finding
• Why De Grey, Infomedia, Northern Star, & SEEK shares are storming higher
• Telstra (ASX:TLS) share price edges higher despite record $1.5 million fine

Motley Fool contributor Lucas Radbourne-Pugh has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Why is the Cyclopharm (ASX:CYC) share price down today? appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/3h1aSge